Scienture Holdings, Inc. (Nasdaq: SCNX) has entered into a securities purchase agreement with institutional investors.
The agreement involves the purchase of 3,225,000 shares of common stock at $1.20 per share in a registered direct offering, with expected gross proceeds of approximately $3.9 million.
Maxim Group LLC is the sole placement agent for the offering, which is set to close on August 15, 2025.
Offering Details
3,225,000 shares of common stock at $1.20 per share in a registered direct offering.
Gross Proceeds
Approximately $3.9 million expected before deduction of fees.
Placement Agent
Maxim Group LLC is the sole placement agent for the offering.
- The offering under an effective shelf registration statement indicates the Company's proactive approach to accessing capital markets.
- This agreement reflects investor confidence in Scienture Holdings' strategic direction and potential for growth.
The securities purchase agreement marks a significant milestone for Scienture Holdings, reinforcing its commitment to advancing pharmaceutical product development and enhancing value for stakeholders.